In 2021, EMA recommended 92 medicines for marketing authorisation. Of these, 53 had a new active substance which had never been authorised in the European Union (EU) before. This is a 35% increase compared to the 39 medicines with a new active substance that were authorised in 2020. The overview of key recommendations in 2021 includes figures on the authorisation of medicines and a selection of new treatments that represent significant progress in their therapeutic areas.
EMA: Human medicines highlights of 2021
February 18, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022